CLAIMS

1. A can for use in a pressurized metered dose inhalers (pMDI) device, said can containing a formulation comprising at least a corticosteroid selected from budesonide or beclomethasone dipropionate (BDP), formoterol fumarate as a LABA agent, and a HFA or HFO propellant selected from 1,1-difluoroethane (HFA152a) or 1,3,3,3-tetrafluoropropene (HFO-1234ze),

being said can internally coated by a coating comprising at least a fluorinated-ethylene-propylene polymer (FEP), and wherein the valve is provided with a gasket made of cycloolefin copolymer (COC), along with two gaskets made of EPDM (a polymer of ethylenepropylenediene monomer) or the valve is provided with two gaskets, both of them made of chlorobutyl polymer.

2. The can according to claim 1, wherein said LABA agent is formoterol fumarate dihydrate.

3. The can according to any one of the preceding claims, containing a formulation further comprising one or more excipients, co-solvents or acids.

4. The can according to claim 3, wherein said co-solvent is an aliphatic alcohol having from 1 to 4 carbon atoms.

5. The can according to claim 4, wherein said aliphatic alcohol is ethanol, preferably anhydrous.

6. The can according to claims 3 to 5, containing a formulation further comprising a mineral or organic acid selected from the group consisting of: hydrochloric, hydrobromic, nitric, fumaric, phosphoric and citric acid.

7. The can according to claim 6, wherein said acid is hydrochloric acid.

8. The can according to any one of the preceding claims, containing a formulation further comprising a low volatility component selected from the group consisting of: glycols, propylene glycol, polyethylene glycol, glycerol or esters thereof, ascorbyl

palmitate, isopropyl myristate.

9. The can according to any one of the preceding claims, containing a formulation in form of a solution.

10. The can according to any one of the preceding claims, containing a formulation having an apparent pH buffered between 2.5 and 5.

11. The can according to claim 10, containing a formulation having an apparent pH buffered between 3 and 4.5.

12. The can according to any one of the preceding claims, wherein the valve is provided with a gasket made of cycloolefin copolymer (COC), along with two gaskets made of EPDM (a polymer of ethylenepropylenediene monomer).

13. The can according to any one of the preceding claims, wherein the valve is provided with two gaskets, both of them made of chlorobutyl polymer.

14. The can according to any one of the preceding claims, wherein the propellant is 1,1-difluoroethane (HFA152a).

15. A pMDI device comprising the can according to any one of the preceding claims.

16. The pMDI device according to claim 15 for the treatment of a respiratory disease selected from asthma and/or COPD.